<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319709</url>
  </required_header>
  <id_info>
    <org_study_id>EFC4846</org_study_id>
    <secondary_id>EudraCT 2005-005597-67</secondary_id>
    <nct_id>NCT00319709</nct_id>
  </id_info>
  <brief_title>An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression</brief_title>
  <acronym>ZEPHIR</acronym>
  <official_title>An Eight-Week, Double-Blind Placebo Controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Elderly Patients With Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly
      patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose
      of SR58611A compared to placebo in elderly patients with depression. The secondary objectives
      are to evaluate the safety of SR58611A and to evaluate the efficacy of SR58611A on disability
      and quality of life in elderly patients with depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.</measure>
  </secondary_outcome>
  <enrollment type="Actual">288</enrollment>
  <condition>Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR58611A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients or inpatients

          -  Major Depressive Disorder (MDD) with a recurrent Major Depressive Episode (MDE)
             according to DSM IV-TR criteria.

          -  MADRS score equal of above 22.

        Exclusion Criteria:

          -  Patients with a current significant risk of suicide in the investigator's clinical
             judgment.

          -  The duration of the current depressive episode is greater than 2 years.

          -  Patients whose current depressive episode is secondary to a general medical condition

          -  Patients with a lifetime history according to MINI at screening of:bipolar disorder,
             psychotic disorder, antisocial personality disorder.

          -  Patients with a current history according to MINI at screening of anxiety disorders,
             alcohol dependence or abuse or substance dependence or abuse

          -  Patients with severe or unstable concomitant medical conditions.

          -  History of seizures other than a single childhood febrile seizure.

          -  Patients with abnormal thyroid functioning.

          -  Patients with clinically significant ECG findings at screening.

          -  Patients who have taken an investigational drug in the last 3 months prior to
             screening.

          -  Any subject who has previously participated in a SR58611A protocol.

          -  Patients with Mini-Mental State Examination (MMSE) score &lt; 25 at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Finland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>antidepressive agents</keyword>
  <keyword>controlled clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amibegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

